June 25, 2026
Leyden Labs
Leyden Labs is developing a Mucosal Protection Platform, a pipeline of nasal sprays that deliver broadly protective antibodies directly to the lining of the nose and throat to protect against airborne viruses.
- Round
- Other
- Amount raised
- —
- Lead investor
- Gates Foundation
- Industry
- Biotechnology
- Headquarters
- Leiden, Netherlands
- Employees
- 51-200
- Website
- www.leydenlabs.com
- View profile →
Other investors
- EIC Fund
- Invest-NL
- ClavystBio
Source: Tech Funding News